EMA Rejects Hybrid MAA for SedRx as Biotron Plans Pivotal Trials

Regulatory Pathway for SedRx Clarified but Complex

Biotron Limited (ASX:BIT) has taken a significant step in clarifying the European regulatory route for its next-generation general anaesthetic, SedRx. Feedback from the European Medicines Agency (EMA) has ruled out the Hybrid Marketing Authorisation Application (MAA) pathway. This approach, which combines existing data from a previously approved drug with new clinical data, is not viable because the reference product, Althesin, is no longer marketed, making comparative bridging studies impossible.

While this narrows regulatory options, it reduces uncertainty and sets the stage for Biotron to work closely with the EMA on a more conventional pathway. This will likely involve pivotal clinical trials to secure marketing authorisation. The company’s ongoing engagement with the EMA will be critical in defining a robust strategy for SedRx’s approval in Europe.

SedRx Development Advances Beyond Anaesthesia

Alongside regulatory discussions, Biotron is actively exploring SedRx’s potential in an additional neuroscientific indication. This involves procuring drug product, developing assays, and initiating animal studies. SedRx’s active ingredient, alfaxalone, harks back to the anaesthetic Althesin, which was withdrawn due to safety concerns unrelated to the API. Early clinical trials suggest SedRx may have advantages over propofol, especially for older adults at risk of post-anaesthetic neurocognitive impairment.

Expanding Antiviral Horizons with BIT-HBV001

Biotron’s lead antiviral candidate, BIT-HBV001, originally developed for Hepatitis B virus (HBV), is showing promise against Hepatitis Delta Virus (HDV) as well. Ongoing cell-based assays at the SCRIPPS Institute in San Diego aim to elucidate the mechanism of action against HDV, a severe co-infection affecting millions worldwide. The ability of BIT-HBV001 to inhibit HDAg production in co-infected cells positions it as a potential component in future functional cure therapies for HBV/HDV infections.

Financial Position and Leadership Changes

Biotron received a $525,869 R&D Tax Incentive rebate for the 2024/25 financial year, providing a welcome boost to its research funding. Quarterly R&D expenditure stood at $410,000 with an additional $141,000 in related staff costs. Payments to related parties, including director fees and salaries, also totalled $141,000.

The company ended the quarter with $1.554 million in cash and equivalents, estimating approximately seven quarters of funding based on current operating cash flows. This financial runway offers some stability as Biotron advances its clinical and regulatory programs.

On the leadership front, Biotron appointed Dr Paul Kasian as Chairman following the retirement of long-serving Chairman Michael J. Hoy. Kasian, previously a Non-Executive Director, now leads the board as the company navigates these critical development phases.